Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2024 | The minimum acceptable performance of blood biomarker tests for diagnosing AD

Suzanne Schindler • 13 Aug 2024
AAIC 2024
Alzheimer’s Disease Dementia

Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses the minimum acceptable performance of blood biomarker tests for clinical use in diagnosing Alzheimer’s disease (AD). She recommends a sensitivity of 90% and a specificity of 85% to avoid getting false positive results from these tests. This can be adjusted slightly in clinics where there is access to confirmatory tests. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Suzanne Schindler

Guidance for using blood-based biomarkers in AD: which test should be used and in which patients?
2:26
Guidance for using blood-based biomarkers in AD: which test should be used and in which patients?
Suzanne Schindler • 19 Apr 2026
Overcoming challenges associated with interpreting blood-based biomarker findings in AD
1:46
Overcoming challenges associated with interpreting blood-based biomarker findings in AD
Suzanne Schindler • 19 Apr 2026
Highlights from CTAD 2025: using blood-based biomarkers for the biological staging of AD
2:20
Highlights from CTAD 2025: using blood-based biomarkers for the biological staging of AD
Suzanne Schindler • 9 Dec 2025
The development and use of biomarkers for combination therapy in Alzheimer's disease
4:53
The development and use of biomarkers for combination therapy in Alzheimer's disease
Suzanne Schindler • 9 Dec 2025

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals